Verrica Pharmaceuticals
VRCA5.3252.80% ( +0.145 )
Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatolo...
- Open
- 5.170
- High
- 5.325
- Low
- 5.235
- Prev. Close
- 5.180
- Volume
- 3.63K
- Turnover
- 19.32K
- Avg Price
- 5.320
- Bid/Ask Ratio
- --
- Amplitude
- 1.74%
- 52wk High
- 9.821
- Volume Ratio
- 0.16
- Turnover Ratio
- 0.05%
Verrica Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$15.54191.91%
Forecast & RatingStrong buy
6analysts
- Strong buy83.33%
- Buy0.00%
- Hold16.67%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 5 hours ago
Verrica Pharmaceuticals schedules conference call to discuss Q2 results, corporate update
- Global Report · 8 hours ago
Fed Rate Jitters Send Ripples Through Fringe Assets and Yield-Sensitive ETFs
- PUBT · Jul 21 at 07:07 AM
Verrica signs exclusive deal with Medomie to market Ycanth in Israel
- Tip Ranks · Jun 22 at 09:15 AM
H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)
- StockTitan · Jun 21 at 11:05 PM
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts | VRCA Stock News
- StockTitan · May 27 at 11:05 PM
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | VRCA Stock News
